Sildenafil modulates the NO pathway via prevention of NO breakdown. Our study aimed to investigate the effect of intravenous maternal sildenafil administration on cardiovascular function in FGR fetuses.
THE EARLY ONSET RISK CALCULATOR TO EVALUATE EARLY ONSET SEPSIS IN INFANTS BORN ?35 WEEKS' GESTATION
Results: Preliminary analysis of one calendar month included 577 infants, with blood cultures taken and empiric antibiotic treatment in 25 (4.3%). All blood cultures were negative. Application of the NEORC would have resulted in 11 (44%) fewer infants having blood cultures taken and empiric antibiotic treatment, 3 of whom had prolonged hospital stays to receive 5 days of antibiotics.
Conclusions: Compared with a risk-based EOS guideline, the NEORC reduced the proportion of infants born ?35 weeks' gestation treated with antibiotics, without missing any cases of EOS. Analysis will continue to include a larger inception cohort as planned. Methods: Retrospective audit by going through medical records.
Results: A total of 21 neonates were included. The underlying condition was imperforate anus in 17, anorectal anomaly in 3 and Hirschsprung disease in 1. The median gestational age was 38 weeks (range 31-40 weeks). 8 were female and 13 were male. The median birth weight centile was 38 (15-62) whereas it was 34 (9-73) at 20 months of age at the time of second follow-up after stoma closure (p = 0.468). The median birth length centile was 47 (26-72) whereas it was 44.5 (36-55) at second follow-up after stoma closure (p = 0.878). The median birth head circumference centile was 34 (23-73) whereas it was 47 (34-72) at second followup after stoma closure (p = 0.786). The physical growth centiles were similar before and after stoma closure.
Conclusions: Physical growth of neonates undergoing colostomy was adequate in the first two years of life. Conclusions: B. breve M-16 V has the potential to reduce the risk of NEC, LOS, PAFF, and mortality in preterm infants. Larger definitive RCTs are needed to confirm these findings.
BIFIDOBACTERIUM BREVE M-16V AS A PROBIOTIC FOR PRETERM INFANTS-

